
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp has demonstrated strong revenue growth, with estimated revenues reaching $9.2 million in Q4 2023, reflecting a significant increase from the previous quarter's $7.35 million. The company anticipates a total revenue growth of 1.5%-2.5% year-over-year, along with full-year growth projected at approximately 14%, indicating continued market adoption and expansion. Furthermore, a gross margin rebound to approximately 70% showcases improved operational efficiency, bolstering the company's financial health and sustaining a positive outlook.
Bears say
CytoSorbents Corp is facing challenges related to gross margin pressure, which could hinder profitability despite an improved topline revenue outlook. The company operates in a volatile environment that includes risks such as fluctuating commodity costs, rising interest rates, and weakened consumer confidence, which may adversely impact its sales performance. Furthermore, consensus estimates for future earnings per share (EPS) reflect a cautious sentiment, with expectations remaining stagnant and indicating potential difficulties in achieving growth.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares